OncoSil Medical has launched a Security Purchase Plan offering discounted shares and free options to eligible shareholders, aiming to accelerate commercialization of its pancreatic cancer treatment device.
- Security Purchase Plan open to eligible Australian and New Zealand shareholders
- Shares offered at $0.003 or 2.5% discount to 5-day VWAP, plus free attaching options
- Options exercisable at $0.003, expiring July 2027, with ASX listing application underway
- Funds raised to support commercialization of OncoSil’s brachytherapy device for pancreatic cancer
- Device holds breakthrough designations and regulatory approvals in multiple regions
Security Purchase Plan Launch
OncoSil Medical Ltd (ASX, OSL) has officially opened its Security Purchase Plan (SPP), inviting eligible shareholders primarily in Australia and New Zealand to acquire new shares at a discounted price. The offer price is set at the lower of $0.003 per share or a 2.5% discount to the five-day volume weighted average price (VWAP) at the close of the offer on 4 July 2025. Each new share purchased under the plan also comes with one free attaching option, exercisable at $0.003 and expiring on 31 July 2027.
Strategic Capital Raising
This capital raising initiative is designed to bolster OncoSil’s efforts to commercialize its innovative OncoSil™ brachytherapy device, a targeted treatment for locally advanced unresectable pancreatic cancer. The device delivers Phosphorous-32 directly into pancreatic tumors under ultrasound guidance, complementing chemotherapy regimens. With pancreatic cancer being notoriously difficult to treat and often diagnosed late, OncoSil’s technology represents a potentially significant advancement in patient care.
Regulatory and Market Progress
OncoSil’s device has already secured breakthrough device designations in the European Union, United Kingdom, and United States, alongside CE Marking approval for marketing within the EU and UK. The company has commenced initial commercial treatments in countries including Spain, Italy, and Israel, and is actively pursuing further market expansion. The SPP proceeds will support these commercialization activities and ongoing clinical trials.
Options Valuation and Trading
The free attaching options included in the SPP have been valued at approximately $0.001 each using the Black-Scholes model, assuming 50% volatility. OncoSil has applied to the ASX for these options to be listed and tradeable, which would provide shareholders with liquidity and flexibility similar to ordinary shares. The success of this application and the market’s reception to these options will be important factors to watch.
Participation Details and Next Steps
Eligible shareholders can apply for up to $100,000 worth of shares through the SPP by 5, 00 pm AEST on 4 July 2025. Participation is optional, and shareholders are encouraged to review the full prospectus and seek professional advice before subscribing. The company reserves the right to vary the closing date in compliance with regulatory requirements.
Bottom Line?
OncoSil’s SPP marks a pivotal step in funding its growth ambitions, with investor uptake and option listing outcomes set to shape its near-term trajectory.
Questions in the middle?
- How will the market respond to the free attaching options once listed on the ASX?
- What level of shareholder participation will the SPP achieve by the closing date?
- How will the additional capital accelerate OncoSil’s commercial rollout and clinical trial progress?